Abviris Deutschland GmbH Revenue and Competitors

Moving from cell to blood based HPV cancer screening, Abviris has developed a new patented generation of Immune Oncology Diagnostics for the early detection of HPV induced cancer, allowing a blood based entire body screen within minutes by using just one drop of blood. Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer. Our patented diagnostics provide a key contribution to a favourable prognosis, such as early tumour detection and enhanced post-therapy patient management. As pioneers in HPV serology, we develop highly innovative solutions, including the Prevo-Check®, the world´s first entire-body screening test for HPV16-induced cancer, which delivers results within minutes using just a single drop of blood.